Actively Recruiting
Study of Adding Local Ablative Therapy to Ongoing Systemic Treatment for Oligoprogressive Lung and Thoracic Cancers
Led by University of California, Davis · Updated on 2026-07-08
100
Participants Needed
1
Research Sites
91 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical benefit of adding locally ablative therapies to ongoing systemic treatment for patients with oligo-progressive solid tumors, specifically in lung and thoracic cancers. This phase 2 pragmatic study aims to measure disease control at three months after local ablative therapy, defined as continuing systemic therapy without changes or permanent discontinuation. The study is conducted at a single site and follows participants for up to five years after receiving local therapy. Participants receive stereotactic ablative radiotherapy SABR or interventional radiology IR ablation therapy based on the treating radiation oncologists or interventional radiologists discretion. These treatments are given in addition to their current systemic therapy, which participants continue with no more than a 30-day planned break to accommodate the local therapy. The study does not use a control group and involves a single treatment arm focusing on ablative local therapy. During the study, participants are monitored for disease control at three months after local therapy, with additional follow-up up to five years. Researchers assess adverse events related to the ablative therapies for up to two years, overall survival for up to one year, and time to treatment failure within one year. Participants undergo regular evaluations to track the effectiveness and safety of combining local ablative therapies with systemic treatment.
CONDITIONS
Brief Title
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
Research Team
O
Office of Clinical Research
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here